{"id":89634,"date":"2026-05-22T13:18:11","date_gmt":"2026-05-22T13:18:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/89634\/"},"modified":"2026-05-22T13:18:11","modified_gmt":"2026-05-22T13:18:11","slug":"europes-drugs-regulator-green-lights-first-oral-weight-loss-drug-politico","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/89634\/","title":{"rendered":"Europe\u2019s drugs regulator green-lights first oral weight-loss drug \u2013 POLITICO"},"content":{"rendered":"<p>Unlike the weekly Wegovy shot, the tablet is only recommended for adults and has to be taken daily. But the pills &#8220;offer an oral alternative to weekly subcutaneous injections that may be more convenient for some patients,&#8221; the EMA said.<\/p>\n<p>Studies have shown that Wegovy pills can help patients lose on average 13.6 percent of their body weight.<\/p>\n<p>The U.S. Food and Drug Administration <a href=\"https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916472\" target=\"_blank\" rel=\"nofollow noopener\">approved<\/a> the oral version of Wegovy in December 2025, and its competitor, Eli Lilly\u2019s pill <a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-weight-loss\" target=\"_blank\" rel=\"nofollow noopener\">Foundayo<\/a>, in April.<\/p>\n<p>The European Commission must now rubber-stamp the EMA\u2019s decision for the Wegovy pill to be officially approved \u2014 usually within a few months.<\/p>\n","protected":false},"excerpt":{"rendered":"Unlike the weekly Wegovy shot, the tablet is only recommended for adults and has to be taken daily.&hellip;\n","protected":false},"author":2,"featured_media":89635,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[47388,33613,272,357,47389,2836,685,76],"class_list":["post-89634","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-drug-and-device-safety","tag-medicines","tag-novo-nordisk","tag-obesity","tag-ozempic-wegovy","tag-patients","tag-regulation","tag-united-states"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116618428863697652","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/89634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=89634"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/89634\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/89635"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=89634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=89634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=89634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}